mfn-cus-2022 | Nanologica

Nanologica Expands Launch Road Show after Good Reception

12 April, 2022

After a successful first activity of the global launch of the company's silica for preparative chromatography, NLAB Saga®, Nanologica expands the road show with participation at additional chromatography conferences. The launch of Nanologica’s silica for preparative chromatography started at the Purify'22 Chromatography Purification Conclave on April 7 in Hyderabad, India, where the products received a very good reception. In light of this, Nanologica has expanded its road show with additional conferences for chromatography. The company

Nanologica to Attend Conferences in Preparative Chromatography

31 March, 2022

Nanologica will be attending several chromatography conferences during the spring in connection to the launch of the company’s silica for preparative chromatography, NLAB Saga®. The road show starts on April 7 at Purify’22 Chromatography Purification Conclave in Hyderabad, India, where Nanologica’s CEO Andreas Bhagwani will give the inaugural address on Pharmaceutical Megatrends and the Fundamental Impact of Chromatography, and where Nanologica’s SVP Chromatography Katarina Alenäs will give a talk on New Generation Silica for Peptide

Trading in Nanologica’s shares on Nasdaq Stockholm commences today

29 March, 2022

Nanologica AB (publ) announces that the company’s shares are admitted for trading on Nasdaq Stockholm's main market today. “Nanologica is about to launch a world-class product within chromatography that can cut costs for insulin manufacturers, which may enable treatment for more diabetes patients. At the same time, we are progressing our unique platform for local delivery of drugs to the lung through internal development, with the goal of giving patients with severe lung diseases access

Nanologica Publishes Prospectus in Connection with the Listing on Nasdaq Stockholm

21 March, 2022

On 11 March 2022, Nanologica AB (publ) announced that Nasdaq Stockholm’s Listing Committee had approved that the company’s shares are admitted to trading on Nasdaq Stockholm’s main market, conditioned upon customary conditions being fulfilled. The prospectus prepared in connection with the listing has today been approved and registered by the Swedish Financial Supervisory Authority and is now available on Nanologica’s website www.nanologica.com and will be made available on the Swedish Financial Supervisory Authority’s website www.fi.se.

Nanologica has been Approved for Listing on Nasdaq Stockholm

11 March, 2022

Nanologica AB (publ) announces that Nasdaq Stockholm's Listing Committee has approved the company’s application for admission to trading of the company’s shares on Nasdaq Stockholm’s main market. The approval is conditioned upon customary conditions being fulfilled, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority. The first day of trading on Nasdaq Stockholm’s main market is scheduled for Tuesday 29 March 2022 and the last day of trading on Spotlight

Nanologica Publishes Annual Report for 2021

9 March, 2022

Nanologica's annual report for the financial year 2021 has been published and is now available on the company's website. The annual report can be downloaded from the company's website www.nanologica.com (Investor Relations/Finansiella rapporter) and is also attached to the press release. An English translation of the annual report is expected to be available on the company's website in mid-March. For further information, please contact: Johanna Johansson, Director IR, Communications and Marketing Ph: +46

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.